EA201990835A3 - Режимы дозирования антипрогестинов - Google Patents

Режимы дозирования антипрогестинов

Info

Publication number
EA201990835A3
EA201990835A3 EA201990835A EA201990835A EA201990835A3 EA 201990835 A3 EA201990835 A3 EA 201990835A3 EA 201990835 A EA201990835 A EA 201990835A EA 201990835 A EA201990835 A EA 201990835A EA 201990835 A3 EA201990835 A3 EA 201990835A3
Authority
EA
Eurasian Patent Office
Prior art keywords
estrogen
endometriosis
present
women
compositions
Prior art date
Application number
EA201990835A
Other languages
English (en)
Other versions
EA201990835A2 (ru
Inventor
Джозеф С. Подольски
Original Assignee
Репрос Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Репрос Терапьютикс Инк. filed Critical Репрос Терапьютикс Инк.
Publication of EA201990835A2 publication Critical patent/EA201990835A2/ru
Publication of EA201990835A3 publication Critical patent/EA201990835A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Настоящее изобретение относится к способам введения композиций, включающих в себя антагонист рецепторов прогестерона, для применения при лечении эстрогензависимых состояний. Изобретение также указывает на способы лечения болей, связанных с эндометриозом. Композиции могут вводиться женщинам, больным эндометриозом, а также женщинам, проходящим лечение эстрогеном и/или селективными модуляторами рецепторов эстрогена (СМРЭ). В некоторых вариантах осуществления настоящее изобретение представляет способ для подавления эндометриального разрастания.
EA201990835A 2008-04-28 2009-04-27 Режимы дозирования антипрогестинов EA201990835A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4847208P 2008-04-28 2008-04-28

Publications (2)

Publication Number Publication Date
EA201990835A2 EA201990835A2 (ru) 2019-08-30
EA201990835A3 true EA201990835A3 (ru) 2019-12-30

Family

ID=40751037

Family Applications (3)

Application Number Title Priority Date Filing Date
EA201990835A EA201990835A3 (ru) 2008-04-28 2009-04-27 Режимы дозирования антипрогестинов
EA201071249A EA201071249A1 (ru) 2008-04-28 2009-04-27 Режимы дозирования антипрогестинов
EA201401347A EA032646B1 (ru) 2008-04-28 2009-04-27 Режимы дозирования антипрогестинов

Family Applications After (2)

Application Number Title Priority Date Filing Date
EA201071249A EA201071249A1 (ru) 2008-04-28 2009-04-27 Режимы дозирования антипрогестинов
EA201401347A EA032646B1 (ru) 2008-04-28 2009-04-27 Режимы дозирования антипрогестинов

Country Status (24)

Country Link
US (2) US8426394B2 (ru)
EP (1) EP2293797B1 (ru)
JP (1) JP5791499B2 (ru)
KR (2) KR20130059442A (ru)
CN (2) CN105616427A (ru)
AR (1) AR071516A1 (ru)
AU (1) AU2009241355B2 (ru)
BR (1) BRPI0911563A2 (ru)
CA (1) CA2722753C (ru)
CL (1) CL2009001010A1 (ru)
DK (1) DK2293797T3 (ru)
EA (3) EA201990835A3 (ru)
ES (1) ES2561810T3 (ru)
IL (1) IL208844A0 (ru)
ME (1) ME01123B (ru)
MX (1) MX2010011272A (ru)
MY (1) MY161059A (ru)
NI (1) NI201000183A (ru)
NZ (1) NZ589533A (ru)
SG (1) SG10201408483QA (ru)
TW (1) TWI477276B (ru)
UA (1) UA102849C2 (ru)
WO (1) WO2009134718A1 (ru)
ZA (1) ZA201007529B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
HUP0900487A2 (hu) * 2009-08-05 2011-03-28 Richter Gedeon Nyrt 17-acetoxi-11ß-[4-(dimetil-amino)-fenil]-21-metoxi-19-norpregna-4,9-dién-3,20-dion új kristályos polimorf módosulata és eljárás elõállítására
UA113283C2 (xx) * 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
NZ702467A (en) 2012-05-31 2016-07-29 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
CN104755087A (zh) * 2012-11-02 2015-07-01 利普生物药剂公司 治疗孕酮依赖性病况的方法和组合物
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
HU230381B1 (hu) * 2014-02-17 2016-03-29 Richter Gedeon Nyrt Ipari eljárás szteroid intermedier előállítására
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2951284A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． ステロイドホルモン薬学的組成物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
US4615697A (en) 1983-11-14 1986-10-07 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5439913A (en) * 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
PT730448E (pt) * 1993-11-16 2002-07-31 Schering Ag Utilizacao de um substrato de sintetase e/ou dador de oxido nitrico ou um inibidor de oxido nitrico para o fabrico de medicamentos para o tratamento de desordens da contractilidade uterina
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
EP0806952B1 (de) * 1995-02-02 2003-04-02 Schering Aktiengesellschaft Verwendung von kompetitiven progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
CA2668824A1 (en) * 1996-05-01 1997-11-06 The Government Of The United States Of America, Represented By The Secre Tary Of The Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
WO1998008471A1 (en) 1996-08-30 1998-03-05 The Population Council, Inc. Vaginal application mifepristone
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6172052B1 (en) 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
EP1008443A1 (de) 1998-12-08 2000-06-14 Alusuisse Technology & Management AG Sterilisierbarer Folienverbund für Verpackungszwecke
US6740645B1 (en) 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
AU4584901A (en) * 2000-03-17 2001-10-15 Us Gov Health & Human Serv Structural modification of 19-norprogesterone i: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
IN191020B (ru) * 2000-03-28 2003-09-13 Dabur Res Foundation
JP3704093B2 (ja) 2000-04-03 2005-10-05 アステンジョンソン・インコーポレイテッド 結束部材及び物体の結束方法
BR0114665A (pt) * 2000-10-18 2004-01-13 Schering Ag Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio
AU2002318225B2 (en) 2001-07-09 2007-12-13 Repros Therapeutics Inc. Methods and materials for the treatment of testosterone deficiency in men
WO2004096151A2 (en) 2003-04-29 2004-11-11 The General Hospital Corporation Methods and devices for the sustained release of multiple drugs
EP1593376A1 (en) 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
BRPI0513141A (pt) * 2004-07-09 2008-04-29 Population Council Inc composição para anel vaginal, e, processo de contracepção a longo prazo
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
DE102005028970A1 (de) * 2005-06-22 2006-12-28 Siemens Ag Piezoakter mit gesteigertem Hubvermögen
DE102005030294A1 (de) * 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
EA017227B1 (ru) 2006-10-24 2012-10-30 Репрос Терапьютикс Инк. Способ лечения эстрогензависимого состояния
EP2125858A2 (en) * 2007-01-17 2009-12-02 Repros Therapeutics Inc. Pharmaceutically acceptable salts of 11-(4-aminophenyl)-19-norpregna-4,9(10)-diene-3,20-dione derivatives
AU2008237246B2 (en) 2007-04-05 2014-06-05 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
PT2148681E (pt) * 2007-04-20 2016-06-17 Preglem Sa Moduladores seletivos da progesterona no tratamento da hemorragia uterina
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
WO2011039680A1 (en) 2009-09-29 2011-04-07 Koninklijke Philips Electronics N.V. Intrauterine electronic capsule for administering a substance

Also Published As

Publication number Publication date
UA102849C2 (ru) 2013-08-27
KR20110014162A (ko) 2011-02-10
US20110046098A1 (en) 2011-02-24
ME01123B (me) 2013-03-20
US20130289008A1 (en) 2013-10-31
NI201000183A (es) 2012-06-06
ZA201007529B (en) 2011-07-27
JP5791499B2 (ja) 2015-10-07
TW200950786A (en) 2009-12-16
MX2010011272A (es) 2010-12-21
EP2293797A1 (en) 2011-03-16
JP2011518845A (ja) 2011-06-30
EP2293797B1 (en) 2015-11-11
EA201990835A2 (ru) 2019-08-30
AR071516A1 (es) 2010-06-23
NZ589533A (en) 2012-06-29
BRPI0911563A2 (pt) 2016-07-12
CN105616427A (zh) 2016-06-01
CL2009001010A1 (es) 2009-06-19
SG10201408483QA (en) 2015-02-27
EA201071249A1 (ru) 2011-08-30
CN102014923A (zh) 2011-04-13
EA201401347A1 (ru) 2015-07-30
MY161059A (en) 2017-04-14
CA2722753A1 (en) 2009-11-05
CA2722753C (en) 2018-07-03
WO2009134718A1 (en) 2009-11-05
ES2561810T3 (es) 2016-03-01
US8426394B2 (en) 2013-04-23
EA032646B1 (ru) 2019-06-28
IL208844A0 (en) 2011-01-31
TWI477276B (zh) 2015-03-21
AU2009241355A1 (en) 2009-11-05
DK2293797T3 (en) 2016-01-11
KR20130059442A (ko) 2013-06-05
US8735381B2 (en) 2014-05-27
WO2009134718A8 (en) 2010-09-23
AU2009241355B2 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
EA201990835A3 (ru) Режимы дозирования антипрогестинов
EA200970409A1 (ru) Композиции и способы, предназначенные для подавления эндометриальной пролиферации
MY161549A (en) Progesterone antagonists such as cdb-4124 in the treatment of breast cancer
ATE514700T1 (de) Neues tetrazyklisches heteroatom mit als sexualsteroidhormon-rezeptormodulatoren geeigneten derivaten
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
DOP2012000246A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
DE602007010781D1 (de) N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid-derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
EP2381957A4 (en) THERAPEUTIC MODULATION OF VAGINAL EPITHELIUM LIMITING LUBRICATION
MX2014004202A (es) Uso post-agudo y profiláctico de progesterona para mejores resultados asociados con concusión.
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
MX2013002390A (es) Tratamiento de infarto de miocardio usando antagonistas de tgf-beta.
EA201171215A1 (ru) Стоматологическое анестезирующее средство для интраназального введения, содержащее тетракаин и вазоконстриктор
BRPI0907220A2 (pt) métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf
WO2009134725A3 (en) Monomethylamine progesteron antagonists such as cdb-4453 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc
MX2010010799A (es) Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.
EA201990106A1 (ru) Режим приема селективного модулятора рецептора прогестерона (sprm)
EA201491614A1 (ru) Способ лечения гинекологических заболеваний
EA201591793A1 (ru) Лактамные соединения в качестве селективных агонистов ep4-рецепторов для применения при лечении опосредованных ep4 заболеваний и состояний
CL2011001034A1 (es) Compuestos derivados de pirrolidina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como endometriosis, fibroides uterinos, menorragia, entre otras.
EA201590522A1 (ru) Способы введения рифаксимина для снижения веса и лечения ожирения
EA201071350A1 (ru) Композиции и способы для лечения воспаления роговицы
TN2015000454A1 (en) Progesterone receptor antagonist dosage form
UA98124C2 (ru) Применение антагониста прогестерона для лечения эндометриоза